menu
Biomarker Market is estimated to be US$ 161.78 Billion by 2030 with a CAGR of 13.1% during the forecast period
Biomarker Market is estimated to be US$ 161.78 Billion by 2030 with a CAGR of 13.1% during the forecast period
The report "Global Biomarkers Market, By Product (Consumables and Services), By Disease Indication (Cancer, Cardiovascular disorders and Others), By Application (Risk assessment, Development of Molecular Diagnostics, Drug Discovery & Development and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Biomarkers market accounted for US$ 47.02 billion in 2020 and is estimated to be US$ 161.78 billion by 2030 and is anticipated to register a CAGR of 13.1%. A biomarker is a characteristic that may be tested and evaluated as a reliable indicator of a physiological or pathological process, as well as the pharmacological response to a therapeutic intervention. Biomarkers can be used to track the progression of diseases, as well as their regression and prognosis after treatment. Macromolecules such carbohydrates, proteins, and lipids, as well as genes, DNA, RNA, platelets, enzymes, and hormones, are all examples of biomarkers. A biomarker is a metabolite, a change in biological structure, or a distinctive trait that aids in the identification of a disease. Biomarkers are classified in a number of ways.

The report "Global Biomarkers Market, By Product (Consumables and Services), By Disease Indication (Cancer, Cardiovascular disorders and Others), By Application (Risk assessment, Development of Molecular Diagnostics, Drug Discovery & Development and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

·         In April 2021, Amgen announced the launch of Biomarker Assist, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist™, eligible patients may save on biomarker testing.

·         In April 2021, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks (cTnT-hs) and better manage heart failure (NT-proBNP).

Analyst View:

Biomarkers are commonly used in areas such as personalised medicine, companion diagnostics, and other diagnostic areas such as drug discovery and development, as well as the assessment of sickness risk. The rising diagnostic applications of biomarkers are expected to drive market expansion in the coming years. Biomarkers play a significant role in personalised medicine since they may be utilized for diagnosis, prognosis, and treatment selection. Personalized medicine has grown in popularity throughout time as a result of the various limitations of traditional diagnosis and treatment techniques. Large sums of money are required for biomarker research, development, and validation. This limits the growth of the biomarkers market, as well as related markets such as diagnostics (in vitro diagnostics or companion diagnostics) and customized pharmaceuticals.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/141

Key Market Insights from the report:

The global Biomarkers market accounted for US$ 47.02 billion in 2020 and is estimated to be US$ 161.78 billion by 2030 and is anticipated to register a CAGR of 13.1%.The Global Biomarkers Market is segmented based on the product, disease indication, application and region.

·         By Product, the market is segmented into Consumables and Services.

·         By Disease Indication, the market is segmented into Cancer, Cardiovascular disorders and Others.

·         By Application, the Global Biomarkers Market is segmented into Risk assessment, Development of Molecular Diagnostics, Drug Discovery & Development and Others.

·         By Region, the Global Biomarkers Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America region is expected to be the largest Biomarkers market.

 

Competitive Landscape:

The key players operating in the global Biomarkers market includes EKF Diagnostics Holdings, Inc., Meso Scale Diagnostics, LLC., Biosims Technologies Sac, Cisbio Bioassays, Signosis, Inc. Qiagen N.V., Perkinelmer, Inc., Merck MilliporeBio-Rad Laboratories, Inc., Enzo Biochem, Inc. and Others.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.